Ipca On Tailspin After Three-Plant FDA Ban
Executive Summary
Ipca Laboratories was pummeled on Indian bourses after the US FDA barred all but one product from three of its facilities that have been grappling with compliance-related issues, piling up more pressure on the firm.
You may also be interested in...
FDA ‘Exception’ For Ipca’s Chloroquine/HCQ Amid Supply Plans From Others
Import alert hit-Ipca gets a temporary reprieve from US FDA for supplies of hydroxychloroquine sulphate and chloroquine phosphate, the antimalarials in the spotlight as potential treatments for COVID-19. But with many firms committing to supplies/donations, analysts appear to be tempering enthusiasm for large windfall gains for the Indian firm.
Data Integrity Lapses Continue To Bedevil Manufacturers
A recent compilation of FDA warning letters shows that data integrity failings continue to plague API and finished drug manufacturing sites in Asia and Europe.
Canada Bans Ipca Imports Based On U.S. FDA Citations
Canada has joined the U.S. in blocking imports of active pharmaceutical ingredients from an Indian plant of Ipca Laboratories.